Citigroup maintains CRISPR Therapeutics at Buy, raises price target to $90 from $88

Citigroup maintained its Buy rating on CRISPR Therapeutics and increased its price target to $90 from $88, suggesting a 73.8% upside from the Nov 4 close of $51.77. Recent analyst price targets for the company range from $52 to $82.

Original reporting
Published Nov 4, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains CRISPR Therapeutics at Buy, raises price target to $90 from $88 — source image
Decision brief

The 30-second read

$CRSPBullishLow
01

Why it matters

The price target increase reflects a modest bullish outlook but does not introduce new company fundamentals.

02

Market read

A small analyst upgrade that may influence short-term trading activity.

03

What to watch

No new clinical or regulatory news accompanies the upgrade.

Relevance 6/10Novelty 6/10Timing: today

Background

Citigroup's analyst note updates its valuation for CRISPR Therapeutics.

Company-level read

Ticker impact

$CRSPBullishMedium confidence
Context

Citigroup raised its price target on CRISPR Therapeutics to $90 from $88.

Expected impact

potential upward pressure as investors price in higher target.

Evidence & confidence

The modest target increase signals confidence but lacks a catalyst, so impact is limited.

Market effects

May slightly boost biotech sector sentiment.

Limited to US biotech investors.

Minimal global effect.

Counterpoint

Target raise could be premature without new data.

Key entities

  • Citigroup

    Equity research firm providing the rating.

  • CRISPR Therapeutics

    Biotech firm developing gene-editing therapies.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.